Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months ...
Diabetes develops when the body fails to manage its blood glucose levels. One form of diabetes causes the body to not produce insulin at all. Called Type 1 diabetes, or T1D, this autoimmune disease ...
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine ...
A vascularized organoid model of hormone-secreting cells in the pancreas has been developed, with potential to improve diabetes research and cell-based therapies. “Our results highlight the importance ...
Researchers have developed a vascularized organoid model of hormone secreting cells in the pancreas. The advance promises to improve diabetes research and cell-based therapies. Researchers led by ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine ...
"Remarkably, we found that R-VECs did adapt when co-transplanted with islets, supporting the islets with a rich mesh of new vessels and even taking on the gene activity "signature" of natural islet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results